Effects of CYP2C9 polymorphism on the pharmacokinetics of irbesartan in healthy Korean subjects

被引：0
|
作者：
Kim, Mi-Jung
Bae, Jung -Woo
Han, Ho-Kyun
Choi, Sun-Ok
Kim, Ok-Hee
Jang, Choon-Gon
Lee, Jin-Hee
Kim, Nam-Tae
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
Irbesartan; CYP2C9; polymorphism; pharmacokinetics;
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [1] Effects of genetic polymorphism of CYP2C9 on the pharmacokinetics of lornoxicam in healthy Korean subjects.
    Bac, J.
    Kim, N.
    Lee, H.
    Lee, J.
    Jung, D.
    Kim, M.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S33 - S34
  • [2] Effects of CYP2C9 polymorphism on the pharmacokinetics and pharmacodynamics of meloxicam in healthy korean subjects.
    Bae, J.
    Kim, M.
    Song, Y.
    Sa, J.
    Choi, C.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S31 - S31
  • [3] Effect of CYP2C9 polymorphism on the pharmacokinetics of candesartan in healthy Korean subjects.
    Lee, Seok-Yong
    Bae, Jung-Woo
    Han, Ho-Kyun
    Kim, Nam-Tae
    Lee, Jin-Hee
    Jang, Choon-Gon
    Jung, Dong-Won
    Lee, Hwan-Joo
    Choi, Sun-Ok
    Kim, Ok-Hee
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 235 - 235
  • [4] CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects
    Chang-Ik Choi
    Mi-Jeong Kim
    Eun-Kyung Chung
    Hye-In Lee
    Choon-Gon Jang
    Jung-Woo Bae
    Seok-Yong Lee
    European Journal of Clinical Pharmacology, 2012, 68 : 149 - 154
  • [5] CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects
    Choi, Chang-Ik
    Kim, Mi-Jeong
    Chung, Eun-Kyung
    Lee, Hye-In
    Jang, Choon-Gon
    Bae, Jung-Woo
    Lee, Seok-Yong
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (02) : 149 - 154
  • [6] EFFECTS OF CYP2C9☆13 ALLELE ON THE PHARMACOKINETICS OF IRBESARTAN
    Park, J., I
    Choi, C., I
    Bae, J. W.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 64 - 64
  • [7] Effects of CYP2C9*13 allele on the pharmacokinetics of Irbesartan
    Lim, Hye-Jin
    Kim, Dong-Hyun
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    PHARMACOTHERAPY, 2015, 35 (11): : E315 - E316
  • [8] Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects
    Nam-Tae Kim
    Chang‑Keun Cho
    Pureum Kang
    Hye-Jung Park
    Yun Jeong Lee
    Jung‑Woo Bae
    Choon-Gon Jang
    Seok-Yong Lee
    Archives of Pharmacal Research, 2022, 45 : 114 - 121
  • [9] Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects
    Kim, Nam-Tae
    Cho, Chang-Keun
    Kang, Pureum
    Park, Hye-Jung
    Lee, Yun Jeong
    Bae, Jung-Woo
    Jang, Choon-Gon
    Lee, Seok-Yong
    ARCHIVES OF PHARMACAL RESEARCH, 2022, 45 (02) : 114 - 121
  • [10] Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects
    Huang, Hang-Xing
    Wu, He
    Zhao, Yingying
    Zhou, Tao
    Ai, Xin
    Dong, Yu
    Zhang, Yan
    Lai, Yong
    XENOBIOTICA, 2021, 51 (05) : 616 - 623
12345